KLP Kapitalforvaltning AS Acquires Shares of 20,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

KLP Kapitalforvaltning AS purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 20,500 shares of the biopharmaceutical company's stock, valued at approximately $1,712,000.

Several other large investors also recently made changes to their positions in the stock. Sei Investments Co. boosted its stake in Intra-Cellular Therapies by 7.8% in the 4th quarter. Sei Investments Co. now owns 197,806 shares of the biopharmaceutical company's stock worth $16,520,000 after purchasing an additional 14,379 shares during the period. American Century Companies Inc. lifted its holdings in shares of Intra-Cellular Therapies by 25.3% in the fourth quarter. American Century Companies Inc. now owns 314,362 shares of the biopharmaceutical company's stock valued at $26,256,000 after purchasing an additional 63,423 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Intra-Cellular Therapies by 18.2% during the fourth quarter. Teacher Retirement System of Texas now owns 28,159 shares of the biopharmaceutical company's stock worth $2,352,000 after buying an additional 4,328 shares during the period. Xponance Inc. grew its holdings in shares of Intra-Cellular Therapies by 4.8% during the fourth quarter. Xponance Inc. now owns 13,609 shares of the biopharmaceutical company's stock worth $1,137,000 after buying an additional 628 shares in the last quarter. Finally, Natixis Advisors LLC raised its position in Intra-Cellular Therapies by 2.0% in the 4th quarter. Natixis Advisors LLC now owns 25,085 shares of the biopharmaceutical company's stock valued at $2,095,000 after buying an additional 502 shares during the last quarter. Institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

ITCI has been the subject of several research reports. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies currently has an average rating of "Hold" and an average price target of $106.23.

Intra-Cellular Therapies Stock Performance

ITCI traded down $0.01 during trading hours on Wednesday, reaching $131.91. The company's stock had a trading volume of 16,062,900 shares, compared to its average volume of 1,464,125. The company's 50-day moving average is $129.43 and its 200-day moving average is $100.82. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The firm has a market cap of $14.05 billion, a PE ratio of -151.62 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.